These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 3701024)

  • 1. Duchenne muscular dystrophy. A rational approach to disease comprehension and therapy.
    Bonsett CA
    Indiana Med; 1986 Mar; 79(3):236-41. PubMed ID: 3701024
    [No Abstract]   [Full Text] [Related]  

  • 2. An Indiana study: an original clinical approach to a fatal metabolic problem.
    Dyken ML
    Indiana Med; 1986 Mar; 79(3):234-5. PubMed ID: 3517137
    [No Abstract]   [Full Text] [Related]  

  • 3. Duchenne's muscular dystrophy: a tissue culture perspective.
    Bonsett CA; Rudman A
    Indiana Med; 1984 Jun; 77(6):446-9. PubMed ID: 6736618
    [No Abstract]   [Full Text] [Related]  

  • 4. Maturational defect of regenerating muscle fibers in cases with Duchenne and congenital muscular dystrophies.
    Miike T
    Muscle Nerve; 1983 Oct; 6(8):545-52. PubMed ID: 6196637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regeneration of muscle in Duchenne muscular dystrophy: an electron microscope study.
    Mastaglia FL; Papadimitriou JM; Kakulas BA
    J Neurol Sci; 1970 Nov; 11(5):425-44. PubMed ID: 5503268
    [No Abstract]   [Full Text] [Related]  

  • 6. X-linked recessive (Duchenne) muscular dystrophy (DMD) and purine metabolism: effects of oral allopurinol and adenylate.
    Thomson WH
    Adv Exp Med Biol; 1984; 165 Pt B():451-6. PubMed ID: 6539047
    [No Abstract]   [Full Text] [Related]  

  • 7. [Structural proteins of the opaque muscle fibers in Duchenne muscular dystrophy].
    Uchino M; Araki S; Yoshida O; Uekawa K
    Rinsho Shinkeigaku; 1985 Feb; 25(2):166-70. PubMed ID: 4017351
    [No Abstract]   [Full Text] [Related]  

  • 8. [Muscle structural proteins of the opaque fibers in Duchenne type muscular dystrophy].
    Uchino M; Araki S; Yoshida O; Uekawa K
    Rinsho Shinkeigaku; 1983 Aug; 23(8):706-10. PubMed ID: 6661873
    [No Abstract]   [Full Text] [Related]  

  • 9. Identifying and circumventing the defect in Duchenne muscular dystrophy: clinical and biochemical restoration after practical intervention.
    Thomson WH
    Med Hypotheses; 1987 Oct; 24(2):187-90. PubMed ID: 3683247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The functional staging of Duchenne muscular dystrophy using in vivo 31P MR spectroscopy.
    Ikehira H; Nishikawa S; Matsumura K; Hasegawa T; Arimizu N; Tateno Y
    Radiat Med; 1995; 13(2):63-5. PubMed ID: 7667509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on progressive muscular dystrophy. II. Relation between clinical effect of adenosinetriphosphate on progressive muscular dystrophy and phosphate compounds in the muscle.
    Nakahara M
    Arzneimittelforschung; 1965 Jul; 15(7):782-5. PubMed ID: 5898681
    [No Abstract]   [Full Text] [Related]  

  • 12. Muscle energy metabolism in Duchenne dystrophy studied by 31P-NMR: controlled trials show no effect of allopurinol or ribose.
    Griffiths RD; Cady EB; Edwards RH; Wilkie DR
    Muscle Nerve; 1985; 8(9):760-7. PubMed ID: 3935926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A correlation of histology and amino acid incorporation studies in Duchenne muscular dystrophy.
    Monckton G; Nihei T
    Neurology; 1968 Mar; 18(3):276. PubMed ID: 5689674
    [No Abstract]   [Full Text] [Related]  

  • 14. Protein degradation in cultured skeletal muscle from Duchenne muscular dystrophy patients.
    Neville HE; Harrold S
    Muscle Nerve; 1985; 8(3):253-7. PubMed ID: 4058470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Focal lesions of muscle in peripheral vascular disease: their comparison with Duchenne muscular dystrophy.
    Engel WK; Hawley RJ
    Trans Am Neurol Assoc; 1976; 101():240-2. PubMed ID: 1028247
    [No Abstract]   [Full Text] [Related]  

  • 16. Intracellular lipid in pseudohypertrophic muscular dystrophy tissue culture.
    Bonsett CA; Rudman A; Elliott AY
    J Indiana State Med Assoc; 1979 Mar; 72(3):184-7. PubMed ID: 217934
    [No Abstract]   [Full Text] [Related]  

  • 17. [Lipoid changes in progressive muscular dystrophy].
    Schellnack K
    Beitr Orthop Traumatol; 1970 Jan; 17(1):91-5. PubMed ID: 5511214
    [No Abstract]   [Full Text] [Related]  

  • 18. Chronic allopurinol and adenine therapy in Duchenne muscular dystrophy: effects on muscle function, nucleotide degradation, and muscle ATP and ADP content.
    Bertorini TE; Palmieri GM; Griffin J; Chesney C; Pifer D; Verling L; Airozo D; Fox IH
    Neurology; 1985 Jan; 35(1):61-5. PubMed ID: 3880875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duchenne muscular dystrophy: normal ATP turnover in cultured cells.
    Fox IH; Shefner R; Palmieri GM; Bertorini TE
    Neurology; 1985 Oct; 35(10):1521-4. PubMed ID: 4033937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The mechanism of muscle fiber breakdown in Duchenne muscular dystrophy--with particular reference to the significance of opaque muscle fiber. (Part 2)].
    Uchino M; Araki S
    Rinsho Shinkeigaku; 1986 Aug; 26(8):841-6. PubMed ID: 3802677
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.